Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. We report the successful long-term mainten...

Descripción completa

Detalles Bibliográficos
Autores principales: Polychronidou, Genovefa, Papakotoulas, Pavlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: March, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636957/
https://www.ncbi.nlm.nih.gov/pubmed/23626560
http://dx.doi.org/10.1159/000350680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636957/
https://www.ncbi.nlm.nih.gov/pubmed/23626560
http://dx.doi.org/10.1159/000350680

Ejemplares similares